News
AORT
40.34
+1.84%
0.73
What To Expect From Artivion’s (AORT) Q4 Earnings
Barchart · 17h ago
Artivion (AORT) Receives a Buy from Lake Street
TipRanks · 1d ago
Weekly Report: what happened at AORT last week (0202-0206)?
Weekly Report · 2d ago
Lake Street Sticks to Their Buy Rating for Artivion (AORT)
TipRanks · 4d ago
Did Strong Aortic Arch Trial Outcomes Just Shift Artivion's (AORT) Investment Narrative?
Simply Wall St · 5d ago
ASG: Difficult To Make A Case For Buying This Underperforming Fund Today
Seeking Alpha · 02/03 15:31
Assessing Artivion (AORT) Valuation After Positive NEXUS TRIOMPHE And AMDS PERSEVERE Trial Updates
Simply Wall St · 02/03 09:15
The Analyst Verdict: Artivion In The Eyes Of 4 Experts
Benzinga · 02/02 22:00
Artivion Price Target Maintained With a $58.00/Share by Needham
Dow Jones · 02/02 18:08
Needham Reiterates Buy on Artivion, Maintains $58 Price Target
Benzinga · 02/02 17:59
Artivion: Positive Clinical Data and Pipeline Progress Support Sustained Growth and Buy Rating
TipRanks · 02/02 17:06
Artivion (AORT) Receives a Buy from Lake Street
TipRanks · 02/02 15:07
Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Artivion (AORT)
TipRanks · 02/02 15:00
Artivion Presents New Clinical Data From NEXUS TRIOMPHE And AMDS PERSEVERE Trials Demonstrating Strong Survival And Durable Outcomes In Aortic Disease
Benzinga · 02/02 13:14
Artivion announces presentations of clinical data from Nexus and AMD trials
TipRanks · 02/02 13:12
Weekly Report: what happened at AORT last week (0126-0130)?
Weekly Report · 02/02 10:07
Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter 2025 Financial Results
PR Newswire · 01/29 21:05
Is Artivion (AORT) Pricing Look Risky After Strong 1-Year Share Price Run?
Simply Wall St · 01/29 14:31
Weekly Report: what happened at AORT last week (0119-0123)?
Weekly Report · 01/26 10:07
Weekly Report: what happened at AORT last week (0112-0116)?
Weekly Report · 01/19 10:12
More
Webull provides a variety of real-time AORT stock news. You can receive the latest news about Artivion, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About AORT
Artivion, Inc. is a medical device company focused on developing solutions that address cardiac and vascular surgeons’ challenges in treating patients with aortic diseases. The Company is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. It has four major product families: aortic stent grafts, surgical sealants, On-X mechanical heart valves and related surgical products, and implantable cardiac and vascular human tissues. Its Medical Devices segment includes sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. Its Preservation Services segment includes services for the preservation of cardiac and vascular implantable human tissues. Aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Surgical sealants include its BioGlue Surgical Adhesive products.